Telo Genomics Corp
3D0A
Company Profile
Business description
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Contact
2255 York Avenue
Suite 203
VancouverBCV6K 1C5
CANT: +1 604 999-3693
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2027
Employees
6
Stocks News & Analysis
stocks
ASX iron ore player downgraded ahead of earnings
Rising costs and delayed production drive fair value cut for ASX iron ore player.
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,405.40 | 59.70 | 0.64% |
| CAC 40 | 8,669.30 | 2.67 | 0.03% |
| DAX 40 | 26,139.03 | 63.32 | -0.24% |
| Dow JONES (US) | 54,523.85 | 437.97 | 0.81% |
| FTSE 100 | 10,888.30 | 8.92 | 0.08% |
| HKSE | 25,915.82 | 62.90 | 0.24% |
| NASDAQ | 26,526.35 | 58.64 | -0.22% |
| Nikkei 225 | 66,300.44 | 2,342.91 | 3.66% |
| NZX 50 Index | 13,997.18 | 93.72 | 0.67% |
| S&P 500 | 7,737.97 | 1.45 | 0.02% |
| S&P/ASX 200 | 9,227.80 | 51.30 | 0.56% |
| SSE Composite Index | 3,878.43 | 56.15 | 1.47% |